STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANIK
  4. [Form 4] Anika Therapeutics, Inc. Insider Trading Activity

[Form 4] Anika Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

CONLEY SHERYL L reported acquisition or exercise transactions in this Form 4 filing.

Anika Therapeutics director Sheryl L. Conley reported an equity award of restricted stock units. She received 10,402 RSUs of common stock as a grant, with no cash paid per share. Each RSU represents the right to receive one share of common stock.

The RSUs vest in full on the earlier of the company’s 2027 annual stockholder meeting or June 18, 2027. After this award, Conley directly holds 52,970 shares of Anika Therapeutics common stock, reflecting her total direct ownership reported in this filing.

Positive

  • None.

Negative

  • None.
Insider CONLEY SHERYL L
Role null
Type Security Shares Price Value
Grant/Award Common Stock 10,402 $0.00 --
Holdings After Transaction: Common Stock — 52,970 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 10,402 units Restricted stock units of common stock awarded to director
Grant price per share $0.0000 Equity award, no cash paid for RSUs
Shares after transaction 52,970 shares Total direct holdings following RSU grant
Vesting deadline June 18, 2027 RSUs vest by earlier of 2027 annual meeting or this date
restricted stock units financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share..."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Company's common stock."
vest in full financial
"The RSUs vest in full on the earlier of the 2027 annual meeting..."
annual meeting of the Company's stockholders regulatory
"The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CONLEY SHERYL L
(Last)(First)(Middle)
C/O ANIKA THERAPEUTICS, INC.
32 WIGGINS AVENUE
(Street)
BEDFORD MASSACHUSETTS 01730
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Anika Therapeutics, Inc. [ ANIK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A10,402(1)A$052,970D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in full on the earlier of the 2027 annual meeting of the Company's stockholders or June 18, 2027.
/s/ Sheryl L. Conley06/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Anika Therapeutics (ANIK) report for Sheryl L. Conley?

Anika Therapeutics reported that director Sheryl L. Conley received 10,402 restricted stock units of common stock as an equity grant. This is a compensation-related award, not an open-market purchase or sale, and increases her reported direct holdings to 52,970 shares.

Are Sheryl L. Conley’s new Anika Therapeutics RSUs an open-market purchase?

No, the 10,402 Anika Therapeutics RSUs granted to Sheryl L. Conley are a compensation award, not an open-market purchase. The Form 4 lists the transaction code as A for grant or award acquisition, with a price per share of $0.0000.

When do Sheryl L. Conley’s Anika Therapeutics RSUs vest?

The RSUs granted to Sheryl L. Conley vest in full on the earlier of Anika Therapeutics’ 2027 annual stockholder meeting or June 18, 2027. Vesting means each restricted stock unit converts into one share of common stock at that time.

How many Anika Therapeutics shares does Sheryl L. Conley own after this Form 4?

Following the RSU grant, Sheryl L. Conley is reported as directly holding 52,970 shares of Anika Therapeutics common stock. This total includes the newly awarded 10,402 restricted stock units, each representing one underlying share upon vesting.

What does transaction code A mean in the Anika Therapeutics (ANIK) Form 4?

In this Anika Therapeutics Form 4, transaction code A indicates a grant, award, or other acquisition of securities. For Sheryl L. Conley, it reflects a compensation-related grant of 10,402 restricted stock units, rather than a market buy or sell transaction.